R. Carroll

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

E. Perez, E. Tan-chiu, A. Brufsky, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up.

E. Perez, G. Warsi, A. Brufsky, 2009 .

An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X.

D. Gilliland, Jay-Jiguang Zhu, C. Willman, 1994, Nucleic acids research.

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Eddie B. S. Tan, Nishit P. Parikh, Rajan K. Patel, 2023, The Lancet.

Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial

E. Tan-chiu, A. Brufsky, W. G. Harker, 2005 .

Effect of oral magnesium supplementation on selected cardiovascular risk factors in non-insulin-dependent diabetics.

D. Cummings, R. Horner, P. Landsman, 1994, Archives of family medicine.

Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.

P. Baas, J. Penrod, H. Ubhi, 2021, Lung cancer.